Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
SAN DIEGO, May 08, 2018 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, publishes scientific posters with dynamic audio narration. More than a dozen posters were presented at the recent American Association of Cancer Research’s (AACR) 2018 meeting and are now available to watch and download, https://www.crownbio.com/posters/
These scientific posters describe innovations in CrownBio’s Internal R&D focusing on preclinical oncology research. The most compelling work is now available on-demand and narrated by CrownBio scientists. The library of poster presentations includes details on the development and application of several innovative humanized models, a new largescale ex vivo PDX drug screening service and a novel IDO1 inhibition assay platform. Collectively, the data demonstrate CrownBio’s unique capacity to enhance knowledge, guide development decisions and advance immunotherapy programs.
“CrownBio is providing unfettered access to CrownBio’s innovative research with scientific colleagues worldwide,” said Dr. Henry Li, CrownBio’s Vice President of Translational Oncology. “We are committed to sharing with scientists globally the cutting-edge tools that are available to accelerate, inform and enlighten contemporary evaluation of cancer therapies and immunotherapies.”
“Crown Bioscience is committed to making valuable contributions to the scientific community,” said Dr. Jean Pierre Wery, Crown Bioscience’s Chief Executive Officer. “By providing these posters, narrated by the experts behind the science, we hope to deliver insights researchers can use to advance their preclinical drug development programs.”
The library of narrated posters can be found on Crown Bioscience’s website, https://www.crownbio.com/posters/
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc. [email protected]
